|This Slide: #73 of 83|
Slide #73. Acorda Therapeutics, Inc. — Neuronex, Inc.
Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis.
Open the ACOR Page at The Online Investor »
Hold (2.00 out of 4)
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite